BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1296 related articles for article (PubMed ID: 34406813)

  • 1. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seropositivity to SARS-CoV-2 in Alberta, Canada in a post-vaccination period (March 2021-July 2021).
    Kanji JN; Nguyen LT; Plitt SS; Charlton CL; Fenton J; Braun S; Marohn C; Lau C; Svenson LW; Hinshaw D; Lutsiak C; Zelyas N; Mengel M; Tipples G
    Infect Dis (Lond); 2022 Sep; 54(9):666-676. PubMed ID: 35642330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights from Patterns of SARS-CoV-2 Immunoglobulin G Serology Test Results from a National Clinical Laboratory, United States, March-July 2020.
    Kaufman HW; Chen Z; Meyer WA; Wohlgemuth JG
    Popul Health Manag; 2021 Feb; 24(S1):S35-S42. PubMed ID: 33216694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.
    Soeorg H; Jõgi P; Naaber P; Ottas A; Toompere K; Lutsar I
    Infect Dis (Lond); 2022 Jan; 54(1):63-71. PubMed ID: 34520315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
    Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
    Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
    JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
    He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
    Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022.
    Duong S; Burtniak J; Gretchen A; Mai A; Klassen P; Wei Y; Loeppky C; Shaw SY; Bullard J; Van Caeseele P; Stein DR
    BMC Public Health; 2023 Dec; 23(1):2420. PubMed ID: 38053033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-Sectional Population-Based Study.
    Moreira-Soto A; Pachamora Diaz JM; González-Auza L; Merino Merino XJ; Schwalb A; Drosten C; Gotuzzo E; Talledo M; Arévalo Ramirez H; Peralta Delgado R; Bocanegra Vargas S; Drexler JF
    mSphere; 2021 Dec; 6(6):e0068521. PubMed ID: 34817236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    Madhi SA; Kwatra G; Myers JE; Jassat W; Dhar N; Mukendi CK; Nana AJ; Blumberg L; Welch R; Ngorima-Mabhena N; Mutevedzi PC
    N Engl J Med; 2022 Apr; 386(14):1314-1326. PubMed ID: 35196424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.
    Doucette EJ; Gray J; Fonseca K; Charlton C; Kanji JN; Tipples G; Kuhn S; Dunn J; Sayers P; Symonds N; Wu G; Freedman SB; Kellner JD
    PLoS One; 2023; 18(4):e0284046. PubMed ID: 37023007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.